Most recently, Dr. Raillard was Executive Director of Chemical Development at XenoPort, Inc. In this role, he was responsible for developing the commercial manufacturing process for Gabapentin enacarbil (Tradename HORIZANT) and for supervising commercial manufacturing campaigns of over twenty metric tons with a per batch size of 800 kilograms. Horizant is approved by the FDA for use in patients with Restless Legs Syndrome and Post-Herpetic Neuralgia. In addition, he was responsible for the development and manufacturing of seven additional APIs in XenoPort’s portfolio, four of which entered clinical trials. Dr. Raillard was a core Chemistry Manufacturing and Controls (CMC) team member in due diligence discussions that led to licensing agreements with GSK and Astellas for Gabapentin enacarbil, Indivior for Arbaclofen Placarbil, and Dr. Reddy’s for XP23829. Dr. Raillard has contributed to CMC filings and interactions with global regulatory authorities across the spectrum of drug discovery, development, and commercialization and including pre-Investigational New Drug Applications, New Drug Applications, and post-approval commitments.
Prior to joining Kodiak, Dr. Raillard held technical positions at Affmax Research Institute where, among other duties, he invented and reduced to practice methods enabling fast scale-up using solid-phase chemistry on custom high-load polymer resins.
Dr. Raillard received his Ph.D. from the ETH Zürich in Switzerland followed by a post-doc at The Scripps Research Institute in La Jolla, CA.